Pilot Study of rhBMP/BCP With or Without the TSRH® Spinal System for Posterolateral Lumbar Fusion in Patients With Degenerative Disc Disease

Degenerative Disc Disease Clinical Trial

Official title:

A Pilot Study of Recombinant Human Bone Morphogenetic Protein-2 and Biphasic Calcium Phosphate With or Without the TSRH® Spinal System for Posterolateral Lumbar Fusion in Patients With Symptomatic Degenerative Disc Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01494441
• Other study ID #: C-9805
• Status: Completed
• Phase: N/A
• Start date: May 1999
• Est. completion date: March 2003

Study information

• Verified date: May 2023
• Source: Medtronic Spinal and Biologics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this pilot clinical trial is to evaluate both device designs (rhBMP-2/BCP and rhBMP-2/BCP/TSRH® spinal System) as methods of facilitating spinal fusion as compared to instrumented fusion with autograft in patients with symptomatic degenerative disc disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 27
• Est. completion date: March 2003
• Est. primary completion date: March 2003
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Has degenerative disc diseases noted by back pain of discogenic origin,with or without leg pain, with degeneration of the disc confirmed by patient history ( e.g., pain [leg, back, or symptoms in the sciatic nerve distribution] function deficit and/or neurological deficit) and radiographic studies ( e.g., CT, MRl, X-Ray,etc.) to include

one or more of the following:

• instability (defined as angular motion > 5° and/or translation > 4 mm, based on Flex/Ext radiographs);
• osteophyte formation;
• decreased disc height;
• thickening of ligamentous tissue;
• disc degeneration or herniation; and/or
• facet joint degeneration.

2. Has preoperative Oswestry score > 30.

3. Has no greater than Grade 1 spondylolisthesis utilizing Meyerding's Classification (Meyerding HW,1932.).

4. Requires fusion of a single level disc space from L1 to S1.

5. Is at least 18 years of age, inclusive, at the time of surgery.

6. Has not responded to non-operative treatment ( e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of at least 6 months.

7. If female of child-bearing potential, who is not pregnant or nursing, and who agrees to use adequate contraception for 16 weeks following surgery.

8. Is willing and able to comply with the study plan and sign the Patient Informed Consent Form.

Exclusion Criteria:

1. Has primary diagnosis of a spinal disorder other than degenerative disc disease with Grade1 or less spondylolisthesis at the involved level.

2. Had previous spinal fusion surgical procedure at the involved level.

3. Require spinal fusion at more than one lumbar level.

4. Has a condition which requires postoperative medications that interfere with fusion, such as steroids.

5. Has been previously diagnosed with osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated.

6. Has presence of active malignancy.

7. Has overt or active bacterial infection, either local or systemic.

8. Is grossly obese, i.e., weight > 40% over ideal for their age and height.

9. Has fever ( temperature >101°F oral) at the time of surgery.

10. Has a documented titanium alloy allergy or intolerance.

11. Is mentally incompetent. If questionable, obtain psychiatric consult.

12. Has a Waddell Signs of Inorganic Behavior score of 3 or greater.

13. Is a prisoner.

14. Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug usage.

15. Is a tobacco user at the time of surgery.

16. Has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of spinal fusion surgery (e.g., NSAIDS, steroids or methotrexate).

17. Has a history of autoimmune disease (Systemic Lupus Erythematosus or Dermatomyositis).

18. Has a history of hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins).

19. Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/BCP implantation.

20. Has received any previous exposure to any/all BMPs of either human or animal extraction.

21. Has a history of severe allergy (anaphylaxis).

22. Has history of endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers- Danlos syndrome, or osteogenesis imperfecta).

Related Conditions & MeSH terms

• Degenerative Disc Disease
• Intervertebral Disc Degeneration
• Spinal Diseases

Intervention

Procedure:
• rhBMP-2/BCP
The rhBMP-2/BCP device component consists of recombinant human Bone Morphogenetic Protein-2 ( rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.

Device:
• rhBMP-2/BCP/TSRH® Spinal System
rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, the TSRH® Spinal System.
• Autograft/TSRH® Spinal System
The control device will be autogenous bone from the iliac crest of the patient used in conjunction with the TSRH® spinal System.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Medtronic Spinal and Biologics

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fusion	Fusion is defined as: Evidence of bridging trabecular bone.; No evidence of motion as defined by: a. No more than 3mm difference in translation on the lateral flexion/extension radiographs determined by superimposing the two views, one upon the other; b. Less than 5° difference in angular motion between flexion and extension as seen on the lateral flexion/extension radiographs; Absence of radiolucent lines completely through the fusion mass.	24 month
Primary	Pain/Disability Status	The self-administered Oswestry Low Back pain Disability Questionnaire will be used. Success for each individual patient will be defined as pain/disability improvement postoperatively according to the following definition: Preoperative Score - Postoperative Score >= 15	24 month
Secondary	Neurological Status Success	Neurological status will be assessed preoperatively and postoperatively using a comprehensive neurological status scale. Neurological status is based on four types of measurements (sections): motor, sensory, reflexes and straight leg raise.	24 month
Secondary	Hip (Donor Site) Pain		24 month
Secondary	General Health Status (SF-36)		24 month
Secondary	Pain Status (back pain, leg pain)		24 month
Secondary	Patient Satisfaction		24 month
Secondary	Patient Global Perceived Effect		24 month
Secondary	Overall Success		24 month